|
|
News Breaks | | | | December 10, 2012 | | 05:29 EDT |  | PLX | Protalix announces first patient treated in Phase I/II study of Fabry patients
Protalix BioTherapeutics announced that the first patient has been treated in the company's phase I/II clinical trial of Fabry patients with PRX-102. PRX-102 is the company's proprietary plant cell-expressed, chemically modified recombinant alpha-galactosidase-A enzyme in development as a long-term enzyme replacement therapy for the treatment of Fabry disease. | |
|
News For PLX From The Last 14 Days Check below for free stories on PLX the last two weeks. |
|
|
| May 16, 2013 | | 11:15 EDT |  | PLX | High option volume stocks: HMY MOLX PLX DSW EGLE
 Subscribe for More Information | |
|
|
|
|
|
|
